U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry RACEMIC
Molecular Formula C18H14F4N2O4S
Molecular Weight 430.3751
Optical Activity ( + / - )
Defined Stereocenters 0 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of BICALUTAMIDE

SMILES

CC(CS(=O)(=O)c1ccc(cc1)F)(C(=Nc2ccc(C#N)c(c2)C(F)(F)F)O)O

InChI

InChIKey=LKJPYSCBVHEWIU-UHFFFAOYSA-N
InChI=1S/C18H14F4N2O4S/c1-17(26,10-29(27,28)14-6-3-12(19)4-7-14)16(25)24-13-5-2-11(9-23)15(8-13)18(20,21)22/h2-8,26H,10H2,1H3,(H,24,25)

HIDE SMILES / InChI
Molecular Formula C18H14F4N2O4S
Molecular Weight 430.3751
Charge 0
Count
Stereochemistry RACEMIC
Additional Stereochemistry No
Defined Stereocenters 0 / 1
E/Z Centers 0
Optical Activity ( + / - )

Description

Bicalutamide (brand name Casodex) is an oral non-steroidal anti-androgen for prostate cancer. It is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate. Bicalutamide competitively inhibits the action of androgens by binding to cytosol androgen receptors in the target tissue. Prostatic carcinoma is known to be androgen sensitive and responds to treatment that counteracts the effect of androgen and/or removes the source of androgen. When CASODEX is combined with luteinizing hormone releasing hormone (LHRH) analog therapy, the suppression of serum testosterone induced by the LHRH analog is not affected. Bicalutamide is well-absorbed following oral administration, although the absolute bioavailability is unknown. Bicalutamide undergoes stereospecific metabolism. The S (inactive) isomer is metabolized primarily by glucuronidation. The R (active) isomer also undergoes glucuronidation but is predominantly oxidized to an inactive metabolite followed by glucuronidation. Both the parent and metabolite glucuronides are eliminated in the urine and feces. The S-enantiomer is rapidly cleared relative to the R-enantiomer, with the R-enantiomer accounting for about 99% of total steady-state plasma levels.

CNS Activity

CNS Non-penetrant
1062
Curator's Comment:: The peripheral selectivity of bicalutamide has been shown to be due to poor penetration across the blood-brain barrier: tissue distribution studies with [3H]bicalutamide show that although it is concentrated in the organs of metabolism and secretion as well as in the prostate, the pituitary glands, and the seminal vesicles, levels in the hypothalamus and the central nervous system (CNS) are much lower than in blood.

Originator

Approval Year

1995
184
Targets

Targets

Primary TargetPharmacologyConditionPotency
Antagonist
2575
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8043
CASODEX

Approved Use

Bicalutamide 50 mg daily is indicated for use in combination therapy with a luteinizing hormone-releasing hormone (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of the prostate. Bicalutamide 150 mg daily is not approved for use alone or with other treatments [see Clinical Studies (14.2)

Launch Date

8.1276482E11
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
810.7 μg/L
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/22331758
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BICALUTAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
202.5 μg × h/mL
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/22331758
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BICALUTAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
5.8 day
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered: GONADORELIN
GONADORELIN
 BICALUTAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
146.4 h
EXPERIMENT
https://www.ncbi.nlm.nih.gov/pubmed/22331758
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
BICALUTAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
4%
DRUG LABEL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
50 mg single, oral
dose: 50 mg
route of administration: Oral
experiment type: SINGLE
co-administered: GONADORELIN
GONADORELIN
 BICALUTAMIDE plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: MALE
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
Other AEs: Gynaecomastia, Breast pain...
Other AEs:
Gynaecomastia (45.2%)
Breast pain (57.1%)
Hot flushes (16.7%)
Constipation (31%)
Dry skin (2.4%)
Insomnia (9.5%)
Rash (11.9%)
Back pain (14.3%)
Asthenia (19%)
Diarrhoea (19%)
Urinary tract infection (16.7%)
Arthralgia (11.9%)
Pharyngitis (14.3%)
Pain (23.8%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
Other AEs: Back pain, Constipation...
Other AEs:
Back pain (6.9%)
Constipation (10.3%)
Libido decreased (50%)
Impotence (57%)
Dyspepsia (6.9%)
Dysuria (6.9%)
Haematuria (6.9%)
Pain (17.2%)
Pelvic pain (6.9%)
Somnolence (6.9%)
Urinary incontinence (6.9%)
Urinary urgency (6.9%)
Weight gain (10.3%)
Gynaecomastia (79%)
Breast tenderness (79%)
Hot flushes (41%)
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Other AEs: General body pain, Back pain...
Other AEs:
General body pain (35%)
Back pain (25%)
Asthenia (22%)
Pelvic pain (21%)
Infection (18%)
Abdominal pain (11%)
Chest pain (8%)
Headache (7%)
Flu syndrome (7%)
Hot flashes (53%)
Hypertension (8%)
Constipation (22%)
Nausea (15%)
Diarrhea (12%)
Liver function test increased (7%)
Dyspepsia (7%)
Flatulence (6%)
Anorexia (6%)
Vomiting (6%)
Anemia (11%)
Peripheral edema (13%)
Weight loss (7%)
Hyperglycemia (6%)
Alkaline phosphatase increased (5%)
Weight gain (5%)
Bone pain (9%)
Myasthenia (7%)
Arthritis (5%)
Fracture pathological (4%)
Dizziness (10%)
Paresthesia (8%)
Insomnia (7%)
Anxiety (5%)
Depression (4%)
Dyspnea (13%)
Cough increased (8%)
Pharyngitis (8%)
Bronchitis (6%)
Pneumonia (4%)
Rhinitis (4%)
Rash (9%)
Sweating (6%)
Nocturia (12%)
Hematuria (12%)
Urinary tract infection (9%)
Gynecomastia (9%)
Impotence (7%)
Breast pain (6%)
Urinary frequency (6%)
Urinary retention (5%)
Urination impaired (5%)
Urinary incontinence (4%)
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
AEs

AEs

AESignificanceDosePopulation
Arthralgia 11.9%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
Rash 11.9%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
Back pain 14.3%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
Pharyngitis 14.3%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
Hot flushes 16.7%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
Urinary tract infection 16.7%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
Asthenia 19%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
Diarrhoea 19%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
Dry skin 2.4%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
Pain 23.8%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
Constipation 31%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
Gynaecomastia 45.2%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
Breast pain 57.1%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
Insomnia 9.5%
600 mg 1 times / day multiple, oral
Highest studied dose
Dose: 600 mg, 1 times / day
Route: oral
Route: multiple
Dose: 600 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
unhealthy, 72.1 years (range: 56-84 years)
n = 42
Health Status: unhealthy
Condition: prostate cancer
Age Group: 72.1 years (range: 56-84 years)
Sex: M
Population Size: 42
Sources:
https://pubmed.ncbi.nlm.nih.gov/16771791/
Constipation 10.3%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
Weight gain 10.3%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
Pain 17.2%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
Hot flushes 41%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
Libido decreased 50%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
Impotence 57%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
Back pain 6.9%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
Dyspepsia 6.9%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
Dysuria 6.9%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
Haematuria 6.9%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
Pelvic pain 6.9%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
Somnolence 6.9%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
Urinary incontinence 6.9%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
Urinary urgency 6.9%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
Breast tenderness 79%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
Gynaecomastia 79%
200 mg 1 times / day multiple, oral
Highest studied dose
Dose: 200 mg, 1 times / day
Route: oral
Route: multiple
Dose: 200 mg, 1 times / day
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
unhealthy, adult
n = 29
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 29
Sources:
https://pubmed.ncbi.nlm.nih.gov/9471040/
Dizziness 10%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Abdominal pain 11%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Anemia 11%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Diarrhea 12%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Hematuria 12%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Nocturia 12%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Dyspnea 13%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Peripheral edema 13%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Nausea 15%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Infection 18%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Pelvic pain 21%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Asthenia 22%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Constipation 22%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Back pain 25%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
General body pain 35%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Depression 4%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Fracture pathological 4%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Pneumonia 4%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Rhinitis 4%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Urinary incontinence 4%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Alkaline phosphatase increased 5%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Anxiety 5%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Arthritis 5%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Urinary retention 5%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Urination impaired 5%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Weight gain 5%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Hot flashes 53%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Anorexia 6%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Breast pain 6%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Bronchitis 6%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Flatulence 6%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Hyperglycemia 6%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Sweating 6%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Urinary frequency 6%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Vomiting 6%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Dyspepsia 7%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Flu syndrome 7%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Headache 7%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Impotence 7%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Insomnia 7%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Liver function test increased 7%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Myasthenia 7%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Weight loss 7%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Chest pain 8%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Cough increased 8%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Hypertension 8%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Paresthesia 8%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Pharyngitis 8%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Bone pain 9%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Gynecomastia 9%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Rash 9%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Urinary tract infection 9%
50 mg 1 times / day multiple, oral
Recommended
Dose: 50 mg, 1 times / day
Route: oral
Route: multiple
Dose: 50 mg, 1 times / day
Co-administed with::
LHRH analog
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
unhealthy, adult
n = 401
Health Status: unhealthy
Condition: prostate cancer
Age Group: adult
Sex: M
Population Size: 401
Sources:
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/020498s028lbl.pdf
Overview

Overview

CYP3A4CYP2C9CYP2D6hERG
substrate
1601

inhibitor
1467
inhibitor
1604
inhibitor
1702

OverviewOther

Other InhibitorOther SubstrateOther Inducer
CYP2C19
1325

CYP1A2
1383

UGT1A9
113

P-gp
1330
UGT1A1
393

UGT1A3
397

UGT1A4
330

UGT1A5
53

UGT1A6
289

UGT1A7
221

UGT1A8
266

UGT1A9
357

UGT1A10
273

UGT2B4
233

UGT2B7
362

UGT2B10
125

UGT2B15
191

UGT2B17
203

UGT2B28
61
CYP
70
Drug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1772
 major [IC50 7 uM]
CYP1A2
1532
 minor [IC50 123 uM]
CYP2C9
1648
 minor [IC50 44 uM]
CYP2C19
1392
 minor [IC50 49 uM]
CYP2D6
1738
 minor [IC50 58 uM]
P-gp
1514
 yes [Inhibition 40 uM]
UGT1A9
118
 yes [Ki 11.9 uM]
CYP
132
 yes
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
CYP3A4
1601
 likely
unlikely (co-administration study)
Comment: this isoenzyme is also responsible for the metabolism of (R)-bicalutamide; (S)-Bicalutamide is metabolised in vitro by CYP3A4
Page: 2.0
UGT1A1
393
 low
UGT1A3
397
 low
UGT1A9
357
 major
UGT1A8
266
 minor
UGT2B7
362
 minor
UGT1A10
273
 no
UGT1A4
330
 no
UGT1A5
53
 no
UGT1A6
289
 no
UGT1A7
221
 no
UGT2B10
125
 no
UGT2B15
191
 no
UGT2B17
203
 no
UGT2B28
61
 no
UGT2B4
233
 no
Sourcing

Sourcing

Vendor/AggregatorIDURL
3B Scientific (Wuhan) Corp
3B2-0243
http://www.3bsc.com/index/pro_info.php?id=19599
AA Blocks
AA00H0UA
https://www.aablocks.com/goods/Goods/detail?id=AA00H0UA
AHH Chemical co.,ltd
API-1229
http://www.ahhchemical.com/product/API-1229.html
AHH Chemical co.,ltd
MT-01087
http://www.ahhchemical.com/product/MT-01087.html
AK Scientific, Inc. (AKSCI)
J10442
http://www.aksci.com/item_detail.php?cat=J10442
Aaron Chemicals
AR00H1M2
http://www.aaronchem.com/90357-06-5
AbMole Bioscience
M1960
http://www.abmole.com/products/bicalutamide.html
Achemo Scientific Limited
AC-13010
http://www.achemo.com/product_view.asp?ID=2900
Achemtek
0104-018953
http://www.achemtek.com/90357-06-5
Acros Organics
AC461000010
https://www.fishersci.com/shop/products/bicalutamide-97-acros-organics/AC461000010
Adooq BioScience
Bicalutamide - Casodex
http://www.adooq.com/bicalutamide-casodex.html
Alfa Chemistry
AP90357065-B
https://reagents.alfa-chemistry.com/product/bicalutamide-cas-90357-06-5-18340.html
Alfa Chemistry
AP90357065-C
https://reagents.alfa-chemistry.com/product/bicalutamide-cas-90357-06-5-18341.html
Alfa Chemistry
AP90357065-A
https://reagents.alfa-chemistry.com/product/bicalutamide-cdx-cas-90357-06-5-18339.html
Alfa Chemistry
90357-06-5
https://www.alfa-chemistry.com/bicalutamide-cas-90357-06-5-item-294076.htm
Alsachim
1265
http://www.alsachim.com/product-C1621-glo.bal-view.html
Ambeed
A176397
https://www.ambeed.com/products/90357-06-5.html
Ambinter
Amb10231002
http://www.ambinter.com/reference/10231002
Angel Pharmatech
AG201149
http://www.angelpharmatech.com/113299-40-4.html
Angel Pharmatech
AG301719
http://www.angelpharmatech.com/90357-06-5.html
Angene
AGN-PC-00TUFT
http://www.angenechemical.com/productshow/AGN-PC-00TUFT.html
ApexBio Technology
A5065
http://www.apexbt.com/bicalutamide.html
Ark Pharm
AK544272
http://www.arkpharminc.com/products/90357-06-5.html
AstaTech, Inc.
21414
http://www.astatechinc.com/CPSResult.php?CRNO=430
Aurora Fine Chemicals LLC
A17.901.727
http://online.aurorafinechemicals.com/info?ID=A17.901.727
AvaChem Scientific
2621
http://www.avachem.com/productSearch.asp?2621
Axon MedChem
3313
https://www.axonmedchem.com/product/3313
BLD Pharm
BD16821
http://www.bldpharm.com/products/90357-06-5.html
BOC Sciences
1185035-71-5
https://www.bocsci.com/bicalutamide-d4-cas-1185035-71-5-item-467499.html
BOC Sciences
1217826-87-3
https://www.bocsci.com/r-bicalutamide-d4-cas-1217826-87-3-item-467500.html
BioChemPartner
BCP02110
http://www.biochempartner.com/90357-06-5-BCP02110
BioCrick
BCC2481
http://www.biocrick.com/Bicalutamide-BCC2481.html
Boerchem
BC204097
http://www.boerchem.com/?product_34304.html
CSNpharm
CSN12437
https://www.csnpharm.com/products/bicalutamide.html
Capot Chemical
18237
http://www.capotchem.com/en/18237.htm
Capot Chemical
PubChem18237
http://www.capotchem.com/en/18237.htm
Chem Scene
CS-1296
http://www.chemscene.com/90357-06-5.html
ChemMol
30101941
http://www.chemmol.com/chemmol/30101941.html
ChemMol
44001697
http://www.chemmol.com/chemmol/44001697.html
ChemMol
49401258
http://www.chemmol.com/chemmol/49401258.html
ChemMol
97900772
http://www.chemmol.com/chemmol/97900772.html
ChemMol
99183973
http://www.chemmol.com/chemmol/99183973.html
Chemspace
CSSB00015190076
https://chem-space.com/CSSB00015190076
Clearsynth
CS-EG-00189
https://www.clearsynth.com/en/CSEG00189.html
Clearsynth
CS-ER-02475
https://www.clearsynth.com/en/CSER02475.html
Clearsynth
CS-O-01015
https://www.clearsynth.com/en/CSO01015.html
Clearsynth
CS-O-07365
https://www.clearsynth.com/en/CSO07365.html
Combi-Blocks
ST-7244
http://www.combi-blocks.com/cgi-bin/find.cgi?ST-7244
DC Chemicals
DC31087
http://www.dcchemicals.com//product_show-ICI_176334.html
Debye Scientific
DB-041165
http://www.debyesci.com/cas_113299-40-4.html
Excenen
EX-A962
http://www.excenen.com/searchresultlist.php?id=90357-06-5
Finetech
FT-0663100
http://www.finetechnology-ind.com/prod/detail/pub/113299-38-0.html
Finetech
FT-0631069
http://www.finetechnology-ind.com/prod/detail/pub/113299-40-4.html
Finetech
FT-0618286
http://www.finetechnology-ind.com/prod/detail/pub/90357-06-5.html
Glentham Life Sciences
GP8076
http://www.glentham.com/products/product/GP8076/
LGC Standards
LGCFOR0894.00
https://www.lgcstandards.com/US/en/p/LGCFOR0894.00
LGC Standards
MM0894.00-0250
https://www.lgcstandards.com/US/en/p/MM0894.00-0250
Lab Network
LN01271632
https://labnetwork.com/frontend-app/p/#!/moleculedetails/LN01271632
Matrix Scientific
146650
https://www.matrixscientific.com/146650.html
MedChem Express
HY-14249
https://www.medchemexpress.com/Bicalutamide.html
OChem
337
http://www.ocheminc.com/index.php?act=psearch&pid=357B065
Parchem
28347
http://www.parchem.com/chemical-supplier-distributor/Bicalutamide-018347.aspx
Parchem
28348
http://www.parchem.com/chemical-supplier-distributor/Bicalutamide-018348.aspx
Selleck Chemicals
S1190
http://www.selleckchem.com/products/Bicalutamide(Casodex).html
Sigma-Aldrich
BP1115_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/bp1115?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
PHR1678_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/phr1678?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
Y0001444_SIAL
https://www.sigmaaldrich.com/catalog/product/sial/y0001444?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
B9061_SIGMA
https://www.sigmaaldrich.com/catalog/product/sigma/b9061?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Sigma-Aldrich
1071202_USP
https://www.sigmaaldrich.com/catalog/product/usp/1071202?utm_source=pubchem&utm_campaign=pubchem_2017&utm_medium=referral
Smolecule
S548655
http://www.smolecule.com/products/s548655
Smolecule
S810223
https://www.smolecule.com/products/s810223
Synblock Inc
SB17301
http://www.synblock.com/product/90357-06-5.html
TCI (Tokyo Chemical Industry)
B3206
http://www.tcichemicals.com/eshop/en/us/commodity/B3206/index.html
THE BioTek
bt-288062
https://www.thebiotek.com/product/inhibitors/bt-288062
Tocris
3389
https://www.tocris.com/products/bicalutamide_3389
TripleBond
CB0180
http://www.triplebond-canada.com/prod/1144/
VladaChem
VL281207-1G
https://www.vladachem.com/product.php?products=90357-06-5
Wuhan Atomole Chemicals Co., Ltd.
AT-9158
http://www.atomole.com/en/products-view.asp?id=129046
Yuhao Chemical
LX2477
http://www.chemyuhao.com/90357-06-5.html
abcr GmbH
AB282481
http://www.abcr.com/shop/en/AB282481
eNovation Chemicals
D672520
https://www.enovationchem.com/ProductDetails.asp?ProductID=D672520
eNovation Chemicals
D767647
https://www.enovationchem.com/ProductDetails.asp?ProductID=D767647
eNovation Chemicals
Y1049756
https://www.enovationchem.com/ProductDetails.asp?ProductID=Y1049756
iChemical
EBD32195
http://www.ichemical.com/products/90357-06-5.html?utm_source=PubChem&utm_medium=website&utm_campaign=product%20catalogs
PubMed

PubMed

TitleDatePubMed
Regulation of GCDFP-15 expression in human mammary cancer cells.
1999 Aug
Rapid and sensitive reporter gene assays for detection of antiandrogenic and estrogenic effects of environmental chemicals.
1999 Mar 1
Androgen sensitivity related proteins in hormone-sensitive and hormone-insensitive prostate cancer cell lines treated by androgen antagonist bicalutamide.
2001
Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex.
2002 Dec 13
Antiandrogenic activities of diesel exhaust particle extracts in PC3/AR human prostate carcinoma cells.
2003 Dec
Androgen dependent regulation of bacillus Calmette-Guerin induced interleukin-6 expression in human transitional carcinoma cell lines.
2003 Nov
Partial agonist/antagonist properties of androstenedione and 4-androsten-3beta,17beta-diol.
2004 Aug
Oestrogen receptor beta is required for androgen-stimulated proliferation of LNCaP prostate cancer cells.
2004 Jun
Coregulator recruitment and histone modifications in transcriptional regulation by the androgen receptor.
2004 Nov
Secretoglobin 2A1 is under selective androgen control mediated by a peculiar binding site for Sp family transcription factors.
2005 Dec
Evaluation of tamoxifen and anastrozole in the prevention of gynecomastia and breast pain induced by bicalutamide monotherapy of prostate cancer.
2005 Feb 1
The ErbB3-binding protein Ebp1 suppresses androgen receptor-mediated gene transcription and tumorigenesis of prostate cancer cells.
2005 Jul 12
Direct agonist/antagonist functions of dehydroepiandrosterone.
2005 Nov
Antiandrogen bicalutamide promotes tumor growth in a novel androgen-dependent prostate cancer xenograft model derived from a bicalutamide-treated patient.
2005 Nov 1
Androgen receptor signaling and vitamin D receptor action in prostate cancer cells.
2005 Sep 1
The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer.
2006 Apr
Influence of bicalutamide with or without tamoxifen or anastrozole on insulin-like growth factor 1 and binding proteins in prostate cancer patients.
2006 Apr-Jun
Distinct regulation by steroids of messenger RNAs for FSHR and CYP19A1 in bovine granulosa cells.
2006 Aug
Prostate specific antigen expression does not necessarily correlate with prostate cancer cell growth.
2006 Jul
GREB1 is a novel androgen-regulated gene required for prostate cancer growth.
2006 Jun 1
DHT and testosterone, but not DHEA or E2, differentially modulate IGF-I, IGFBP-2, and IGFBP-3 in human prostatic stromal cells.
2006 May
Androgen induction of prostate cancer cell invasion is mediated by ezrin.
2006 Oct 6
Dual androgen-response elements mediate androgen regulation of MMP-2 expression in prostate cancer cells.
2007 Jan
Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs.
2007 Jul 17
PC-1/PrLZ contributes to malignant progression in prostate cancer.
2007 Sep 15
A novel dietary flavonoid fisetin inhibits androgen receptor signaling and tumor growth in athymic nude mice.
2008 Oct 15
Interactions of methoxyacetic acid with androgen receptor.
2009 Jul 15
Testosterone, not 5α-dihydrotestosterone, stimulates LRH-1 leading to FSH-independent expression of Cyp19 and P450scc in granulosa cells.
2011 Apr
Dehydroepiandrosterone post-transcriptionally modifies CYP1A2 induction involving androgen receptor.
2013 May 25
Patents

Patents

JP2005060302A
3
JP2006265244A
8
JP2011528275A
417
JP4397691B2
22

Sample Use Guides

In Vivo Use Guide
one 50 mg tablet once daily (morning or evening), with or without food
Route of Administration: Oral
In Vitro Use Guide
Primary tumor cultures and PCa cell lines were treated with bicalutamide (0.1-10 uM) in the presence of dehydrotestosterone (10(-12) M) for 4 days. After bicalutamide treatment, no significant differences in the concentration that inhibits 50% were found among the different tumor cell lines (P = .081).
Substance Class Chemical
Created
by admin
on Fri Jun 25 21:02:59 UTC 2021
Edited
by admin
on Fri Jun 25 21:02:59 UTC 2021
Record UNII
A0Z3NAU9DP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BICALUTAMIDE
EP   HSDB   INN   JAN   MART.   MI   ORANGE BOOK   USAN   USP   USP-RS   VANDF   WHO-DD  
USAN   INN  
Official Name English
BICALUTAMIDE [HSDB]
Common Name English
ICI176,334-1
Code English
BICALUTAMIDE [ORANGE BOOK]
Common Name English
BICALUTAMIDE [USP]
Common Name English
BICALUTAMIDE [USP-RS]
Common Name English
BICALUTAMIDE [USAN]
Common Name English
ICI-176334
Code English
BICALUTAMIDE [EP MONOGRAPH]
Common Name English
PROPANAMIDE, N-(4-CYANO-3-(TRIFLUOROMETHYL)PHENYL)-3-((4-FLUOROPHENYL)SULFONYL)-2-HYDROXY-2-METHYL-, (+/-)-
Systematic Name English
(+/-)-4'-CYANO-.ALPHA.,.ALPHA.,.ALPHA.-TRIFLUORO-3-((P-FLUOROPHENYL)SULFONYL)-2-METHYL-M-LACTOTOLUIDIDE
Common Name English
BICALUTAMIDE [USP MONOGRAPH]
Common Name English
BICALUTAMIDE [JAN]
Common Name English
BICALUTAMIDE [INN]
Common Name English
ICI 176,334
Code English
BICALUTAMIDE [MART.]
Common Name English
BICALUTAMIDE [VANDF]
Common Name English
NSC-759816
Code English
BICALUTAMIDE [MI]
Common Name English
CASODEX
Brand Name English
Classification Tree Code System Code
WHO-VATC QL02BB03
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
NDF-RT N0000000243
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
WHO-ATC L02AE51
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
NCI_THESAURUS C146993
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
WHO-ATC L02BB03
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
NDF-RT N0000175560
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
LIVERTOX 105
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
Code System Code Type Description
FDA UNII
A0Z3NAU9DP
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
USP_CATALOG
1071202
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY USP-RS
WIKIPEDIA
BICALUTAMIDE
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
DRUG CENTRAL
367
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
EVMPD
SUB05817MIG
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
PUBCHEM
2375
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
EPA CompTox
90357-06-5
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
IUPHAR
2863
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
MESH
C053541
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
INN
7021
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
NCI_THESAURUS
C1599
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
RXCUI
83008
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY RxNorm
CAS
90357-06-5
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
ChEMBL
CHEMBL409
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
HSDB
7655
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
MERCK INDEX
M2474
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY Merck Index
DRUG BANK
DB01128
Created by admin on Fri Jun 25 21:02:59 UTC 2021 , Edited by admin on Fri Jun 25 21:02:59 UTC 2021
PRIMARY
Related Record Type Details
Structure of BICALUTAMIDE, (R)-
ACTIVE ISOMER -> PARENT
Structure of BICALUTAMIDE, (S)-
INACTIVE ISOMER -> PARENT
Bicalutamide is a racemate and its antiandrogenic activity resides almost exclusively in the (R)-enantiomer, with little, if any, activity in the (S)-enantiomer.
Structure of BICALUTAMIDE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
EP
ANDROGEN RECEPTOR
TARGET -> INHIBITOR
Structure of BICALUTAMIDE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (HPLC)
USP
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
BINDING
ANDROGEN RECEPTOR
TARGET -> AGONIST
BINDING
Related Record Type Details
Structure of BICALUTAMIDE SULFIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 2-FLUORO-4-DESFLUORO BICALUTAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DEOXYBICALUTAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of 4-AMINO-2-(TRIFLUOROMETHYL)BENZONITRILE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DESFLUORO BICALUTAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of DEOXYBICALUTAMIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of BICALUTAMIDE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966